Genmab A/S reported that worldwide net trade sales of DARZALEX, including DARZALEX FASPRO, totaled USD 3,237 million in the first quarter of 2025. These sales figures were reported by Johnson & Johnson, Genmab's partner for daratumumab.
The strong performance was observed both in the U.S. and internationally, contributing to Genmab's royalty revenues. DARZALEX continues to be a significant driver of recurring revenue for the company.
Genmab receives royalties on these global net sales of DARZALEX, which are a substantial and consistent part of its financial performance. The continued growth in DARZALEX sales underpins Genmab's financial strength.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.